ArticleWorld journal of gastrointestinal endoscopy2025
Impact of periampullary diverticulum on the incidence of post-endoscopic retrograde cholangiography pancreatitis.
Article in World journal of gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriampullary diverticulum (PAD) is a common anatomical variant, but its association with post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) remains controversial. While PAD may alter ampullary anatomy, increasing technical difficulty during ERCP, existing studies report inconsistent findings on its role in PEP pathogenesis. We hypothesize that PAD presence, particularly type B, shows a significant association with PEP development and may interact with procedural factors like pancreatic duct guidewire insertion.
aimTo examine the association between PAD (including subtypes A/B) and PEP incidence after ERCP for choledocholithiasis.
methodsWe conducted a retrospective cohort study of 615 patients undergoing ERCP at two tertiary hospitals from 2023 to 2025. Participants were stratified into PAD (
resultsPAD prevalence was 29.8% (183/615). PEP occurrence was more frequent in PAD patients [15.3% (28/183)] than in non-PAD patients [4.2% (18/432)], odds ratio (OR) = 3.86, 95% confidence interval: 2.03-7.35,
conclusionPAD, particularly type B, is independently associated with PEP after ERCP. Patients with these features, especially those with hypertension or pancreatic duct instrumentation, may benefit from enhanced monitoring and prophylaxis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.